Literature DB >> 28460409

Tranexamic Acid Reduces Occult Blood Loss, Blood Transfusion, and Improves Recovery of Knee Function after Total Knee Arthroplasty: A Comparative Study.

Wei Liu1, Chunmei Yang1, Xiujun Huang1, Ruizhong Liu1.   

Abstract

This study intends to explore the effects of tranexamic acid (TA) on occult blood loss, blood transfusion, and recovery of knee function in patients undergoing total knee arthroplasty (TKA). From October 2013 to April 2015, 224 patients undergoing TKA were enrolled in this study. These patients were randomly assigned into the control group (intravenous infusion of normal saline), 10 mg/kg TA group (intravenous infusion of 10 mg/kg TA) and 15 mg/kg TA group (intravenous infusion of 15 mg/kg TA). Compared with the control group, the 10 and 15 mg/kg TA groups were lower in postoperative blood loss, occult blood loss, blood transfusion rate, and volume. In comparison to the control group, hemoglobin levels were lower and the number of red blood cells was higher at 7 days after surgery in the 10 and 15 mg/kg TA groups. Higher fibrinogen levels and lower prothrombin time (PT), activated partial thromboplastin time, D-dimer levels, thrombin time, lower the visual analog scale/score, and circumference diameter of knee joint were observed in the 10 and 15 mg/kg TA groups compared with the control group at 7 and 14 days after surgery. At 1 and 3 months after surgery, the knee joint range of motion scores, Hospital for Special Surgery scores, and Knee Society Score were increased in 10 and 15 mg/kg TA groups in comparison to the control group. TA could reduce occult blood loss and blood transfusion rate and improve recovery of knee function in patients undergoing TKA. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28460409     DOI: 10.1055/s-0037-1602248

Source DB:  PubMed          Journal:  J Knee Surg        ISSN: 1538-8506            Impact factor:   2.757


  7 in total

1.  Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality: A Systematic Review, Meta-analysis, and Meta-regression.

Authors:  Isabel Taeuber; Stephanie Weibel; Eva Herrmann; Vanessa Neef; Tobias Schlesinger; Peter Kranke; Leila Messroghli; Kai Zacharowski; Suma Choorapoikayil; Patrick Meybohm
Journal:  JAMA Surg       Date:  2021-04-14       Impact factor: 14.766

Review 2.  Oral tranexamic acid reduces blood loss in total-knee arthroplasty: A meta-analysis.

Authors:  Hua Li; Liqun Bai; Yunhai Li; Zhiyuan Fang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

3.  Intra-articular vs. intravenous administration: a meta-analysis of tranexamic acid in primary total knee arthroplasty.

Authors:  Jin Li; Ruikang Liu; Saroj Rai; Renhao Ze; Xin Tang; Pan Hong
Journal:  J Orthop Surg Res       Date:  2020-12-02       Impact factor: 2.359

4.  Complications of Tranexamic Acid in Orthopedic Lower Limb Surgery: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Davide Reale; Luca Andriolo; Safa Gursoy; Murat Bozkurt; Giuseppe Filardo; Stefano Zaffagnini
Journal:  Biomed Res Int       Date:  2021-01-16       Impact factor: 3.411

5.  Usefulness of an accelerometer-based navigation system in bilateral one-stage total knee arthroplasty.

Authors:  Artit Laoruengthana; Piti Rattanaprichavej; Thanawat Tantimethanon; Watcharapong Eiamjumras; Passakorn Teekaweerakit; Krit Pongpirul
Journal:  BMC Musculoskelet Disord       Date:  2021-02-10       Impact factor: 2.362

6.  Is tranexamic acid effective on hidden blood loss in patients during total knee arthroplasty?

Authors:  Sualp Turan; Olgun Bingöl
Journal:  Jt Dis Relat Surg       Date:  2020

7.  Multiple-dose tranexamic acid for perioperative blood loss in total knee arthroplasty in patients with rheumatoid arthritis:a single-blinded, randomised, parallel-controlled study protocol in China.

Authors:  Bing-Xin Kang; Hui Xu; Chen-Xin Gao; Sheng Zhong; Jing Zhang; Jun Xie; Song-Tao Sun; Ying-Hui Ma; Wei-Tao Zhai; Lian-Bo Xiao
Journal:  BMJ Open       Date:  2020-08-20       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.